Boehringer Ingelheim abandons biosimilar sales outside the U.S. - STAT

Boehringer Ingelheim abandons biosimilar sales outside the U.S. - STAT

Who needs Europe, anyway?

The drug maker Boehringer Ingelheim is not faring well in the continent, and is currently pressing ahead with a lawsuit to get its rheumatoid arthritis medicine into the market there. In the meantime, though, the company sees the situation in the United States as a good bit rosier.

Boehringer Ingelheim won U.S. and European Union approval to sell a biosimilar version of Humira, which is called Cyltezo, last year. But “at this point in time, future biosimilars activities will be driven out of the U.S. market, including partnership opportunities, while… stopping development activities for the rest of the world,” a company spokesman told BioProcess Insider, which first reported the decision.

As STAT's Ed Silverman notes, there's logic in that: On this side of pond, there's a scramble to get a piece of the biosimilar market before it's to late.

Read more.